BioSpace News Archive

Massachusetts General Hospital and ElevateBio, a cell and gene therapy holding company, announced that they have entered into a 10-year alliance agreement.

Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, announces the acquisition of Breath Therapeutics and its subsidiaries for € 140 million

Patrick Lupinetti to share how Augmented Unique Device Identifier (AUDI) information on coronary artery stents provided by FDB can be used to enhance surgical point-of-care and outcomes studies

BrainScope announced that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion.

Snap Bio, Inc. and Torrey Pines Investment announced that their joint early drug discovery program within the framework of the i2020 Accelerator has resulted in achieving the projected milestone in developing several small molecule lead candidates for treatment of Hepatocellular carcinoma and Hepatoblastoma.

Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced that the U.S. Food and Drug Administration has accepted for filing the company’s New Drug Application for accelerated approval of tazemetostat, its lead investigational agent.

Sales were down 2.6 percent to $8.2 billion. Organic local-currency sales decreased 0.9 percent while acquisitions, net of divestitures, increased sales by 0.1 percent. Foreign currency translation decreased sales by 1.8 percent year-on-year.

Penta ID Innovation, a recently established SMO stemmed from the Penta Global Paediatric Research Network, and CROMSOURCE, an international contract research organization providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries, announced their partnership focused on improving drug development for paediatric patients.

PathMaker Neurosystems Inc., a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with spasticity and paralysis announces the first publication of clinical trial results for its MyoRegulator® device for the non-invasive treatment of spasticity.

Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced executive management appointments that organizationally support the Company’s long-term strategy.